Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Denali Therapeutics Inc (DNLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8143
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. The company’s proprietary drug delivery platform technologies include antibody transport vehicle and enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other indications. The company has development and commercialization rights to all of its programs, including the programs partnered with Takeda. Denali Therapeutics is headquartered in South San Francisco, California, the US.

Denali Therapeutics Inc (DNLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Partnerships 16
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson’s Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Licensing Agreements 23
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Equity Offering 27
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Acquisition 38
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc – Key Competitors 40
Denali Therapeutics Inc – Key Employees 41
Denali Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 09, 2018: Denali Therapeutics reports second quarter 2018 financial results 43
May 11, 2018: Denali Therapeutics Reports First Quarter 2018 Financial Results 44
Mar 19, 2018: Denali Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 45
Corporate Communications 46
Aug 07, 2018: Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson's Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc, Key Competitors 40
Denali Therapeutics Inc, Key Employees 41
Denali Therapeutics Inc, Subsidiaries 42

List of Figures
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Steel Dynamics Inc:戦略・SWOT・企業財務分析
    Steel Dynamics Inc - Strategy, SWOT and Corporate Finance Report Summary Steel Dynamics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Range Energy Resources Inc (RGO):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Energy Resources Inc (Range Energy), formerly Hawkstone Energy Corp, is an oil and gas company that offers exploration and development services. The company acquires, explores and produces minerals, and oil and gas resource properties. It holds interests in Khalakan Production Sharing …
  • Commonwealth Scientific and Industrial Research Organisation:電力:M&Aディール及び事業提携情報
    Summary Commonwealth Scientific and Industrial Research Organisation (CSIRO) is a national science agency that conducts research in climate adaptation, bio-security, renewable and energy, farming and food production, and information technology, and mining and manufacturing services, and others. The …
  • The Cumberland Insurance Group:企業の戦略・SWOT・財務情報
    The Cumberland Insurance Group - Strategy, SWOT and Corporate Finance Report Summary The Cumberland Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Lancer Systems L.P.:企業の戦略・SWOT・財務情報
    Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report Summary Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Biocodex Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Biocodex Inc (Biocodex), a subsidiary of Biocodex, is a pharmaceutical company that manufacturs and distributs probiotic drug products. The company provides products such as Saccharomyces boulardii CNCM I-745 that has a positive effect on the gut's microflora. It also provides Florastor, a y …
  • Neuren Pharmaceuticals Ltd (NEU):企業の財務・戦略的SWOT分析
    Summary Neuren Pharmaceuticals Ltd (Neuren Pharma) is a biopharmaceutical company that develops drugs for brain injury, neurodevelopmental and neurodegenerative disorders. The company provides pipeline products such as trofinetide and NNZ-2591. Its trofinetide has a pharmacokinetic profile, which is …
  • Owensboro Municipal Utilities:企業の戦略的SWOT分析
    Owensboro Municipal Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • FortisBC Inc:企業の戦略的SWOT分析
    FortisBC Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Ding He Mining Holdings Ltd:企業のM&A・事業提携・投資動向
    Ding He Mining Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ding He Mining Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Journey Energy Inc (JOY):企業の財務・戦略的SWOT分析
    Summary Journey Energy Inc (Journey Energy), a subsidiary of Maples Investments LP, is an oil and gas company that offers exploration, development and production oil and natural gas assets. The company provides horizontal and multi-frac drilling, and secondary recovery methods that helps in acquirin …
  • Odfjell Drilling Ltd (ODL):石油・ガス:M&Aディール及び事業提携情報
    Summary Odfjell Drilling Ltd (Odfjell) is an integrated offshore drilling and oil service company. It operates a fleet of harsh and ultra-deepwater mobile offshore drilling units and provides platform drilling and well services. The company's drilling technology offers conceptual engineering and des …
  • Allgeier SE (AEIN):企業の財務・戦略的SWOT分析
    Allgeier SE (AEIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • TOWER Limited:企業の戦略・SWOT・財務分析
    TOWER Limited - Strategy, SWOT and Corporate Finance Report Summary TOWER Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • China Resources Wandong Medical Equipment Co Ltd (600055):医療機器:M&Aディール及び事業提携情報
    Summary China Resources Wandong Medical Equipment Co Ltd (Wandong Medical Equipment), formerly Beijing Wandong Medical Equipment Co Ltd, a subsidiary of Beijing Pharmaceutical Group Co Ltd, is a medical device company that develops and markets medical devices and equipment. The company’s products in …
  • King Yuan Electronics Co Ltd (2449):企業の財務・戦略的SWOT分析
    King Yuan Electronics Co Ltd (2449) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Kenra Professional, LLC:企業の戦略・SWOT・財務分析
    Kenra Professional, LLC - Strategy, SWOT and Corporate Finance Report Summary Kenra Professional, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • CollPlant Ltd (CLGN):医療機器:M&Aディール及び事業提携情報
    Summary CollPlant Holdings Ltd (CollPlant) is a regenerative medicine company that carries out development and commercialization of tissue repair products. The company offers orthobiologics, wound care, and pipeline products. Its orthobiologics products include VergenixSTR and VergenixBVF. CollPlant …
  • Seylan Bank Plc:企業の戦略・SWOT・財務分析
    Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Seylan Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Xero Ltd (XRO):企業の財務・戦略的SWOT分析
    Xero Ltd (XRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆